Joel Baglole

Joel Baglole

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

Newegg Barks for SHIB as Shiba Inu Prices Rocket Higher

Cryptocurrency Shiba Inu is rallying on news that it is being listed on an exchange and a major retailer will accept it as payment.

CPIX Stock Alert: Cumberland Pharma Doubles on FDA Approval News

Cumberland Pharmaceuticals stock is up more than 90% in morning trading after the FDA approved the expanded use of its pain medication.

Buy Amazon Before It Gets More Expensive

Amazon's recent underperformance is likely to end in the New Year. There are favorable conditions that should give a boost to AMZN stock.

It’s a Good Time to Buy Square Stock While It’s Still on Sale

What will it take to get financial technology company Square's stock moving in the right direction again? The San Francisco-based digital payments company's stock has been slumping since the start of August and, at $196.90 a share, is now down 37.98% from its 52-week high of $289.23 reached on August 5.

NRXP Stock Surges on Latest Covid-19 Update From NRx Pharmaceuticals

News that NRx Pharmaceuticals' Covid-19 treatment helps improve survivability in critical patients is sending NRXP stock higher today.